Introduction
============

Community acquired pneumonia (CAP) is common, affecting between 5 and 11 individuals per 1,000 of the adult population each year \[[@B1],[@B2]\] and is the commonest cause of sepsis, severe sepsis and septic shock \[[@B3]\]. Between 22 and 42% of patients require hospital admission \[[@B1],[@B2],[@B4]\] of whom 5 to 10% will be admitted to an ICU \[[@B5]-[@B7]\]. Hospital and ICU admission rates for CAP are increasing for all ages \[[@B8]\]. An ageing, more vulnerable population, earlier recognition of deteriorating patients and better availability and use of intensive care beds may in part explain this increase.

A number of investigators have examined the clinical and microbiological factors that might affect the outcome from severe CAP \[[@B5]-[@B7],[@B9]-[@B23]\], but these studies have often been relatively small, with considerable heterogeneity in both the inclusion criteria and outcome measures. As a consequence reported mortality rates have varied and there has been uncertainty regarding the most important risk factors for death. A number of more recent, larger studies have focussed on identifying patients with CAP at increased risk of severe sepsis and death, as well as those who may require ventilator or vasopressor support \[[@B3],[@B24]-[@B26]\]. One of these studies provides outcome data at 90 days for the smaller subgroup of patients with severe sepsis admitted to the ICU \[[@B3]\], and another \[[@B24]\] reports microbiological findings and 90-day mortality in a subgroup of 170 patients admitted to the ICU.

The aim of the study reported here was to define the clinical characteristics, microbiological aetiology, outcomes and independent risk factors for mortality in a large, contemporary cohort of patients with severe CAP admitted to ICUs across Europe. By using such a large database with clear censor data for mortality we hoped to overcome some of the deficiencies of previous studies.

Materials and methods
=====================

The GenOSept study was conceived by the European Critical Care Research Network (ECCRN), the research arm of the European Society for Intensive Care Medicine (ESICM) with the aim of defining genetic influences on the host response and outcomes in patients with sepsis. GenOSept is a pan-European study that has recorded comprehensive phenotypic data and obtained DNA from a large cohort of patients admitted to ICU with sepsis due to CAP, peritonitis, meningococcal disease or pancreatitis. Ethics approval was granted nationally, for individual centres, or for both. Written, informed consent was obtained from all patients or a legal representative. Patients reported here were recruited into GenOSept from 102 centres across 17 countries (see Additional file [1](#S1){ref-type="supplementary-material"} for contributors) over a 4-year period between September 2005 and October 2009.

Inclusion criteria were as follows: admission to a high dependency unit (HDU) or ICU with CAP, and age over 18 years. The diagnosis of CAP was defined as a febrile illness associated with cough, sputum production, breathlessness, leucocytosis and radiological features of pneumonia acquired in the community or within less than 2 days of hospital admission \[[@B24]\]. The diagnosis of sepsis was based upon the International Consensus Criteria published in 2003 \[[@B27]\]. Patients were further sub-classified according to the criteria for severe sepsis and septic shock.

Exclusion criteria were as follows: patient or legal representative unwilling or unable to give consent; patient under 18 yrs of age; patient pregnant; advanced directive to withhold or withdraw life-sustaining treatment or admitted for palliative care only (please see also Additional file [1](#S1){ref-type="supplementary-material"}).

Patients were observed until death or for a maximum of 6 months. In those who had died between ICU discharge and 6-month follow-up the date of death was recorded. Specific data was recorded in the electronic case report form (eCRF) to allow calculation of the acute physiology and chronic health evaluation II (APACHE II) and sequential organ failure assessment (SOFA) scores \[[@B28],[@B29]\]. The Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) criteria were used for the diagnosis of severe CAP \[[@B30]\]. Co-morbidities were recorded according to the modified Charlson scoring system \[[@B31]\]. Chest radiograph appearances were recorded as: 1) lobar, 2) localised or 3) diffuse bilateral. Investigators were also asked to consider the differential diagnosis of cardiogenic pulmonary oedema in those with diffuse pulmonary infiltrates. Microbiological investigations were performed according to local policies and practices. Investigators recorded the microbiological findings, including the organism(s) isolated, the source of the organism and the use of serology.

Statistical methods
-------------------

Mortality at 28 days and at 6 months were chosen as primary endpoints. Univariate analysis was performed using a Cox proportional hazards model, adjusted for age and gender. Variables considered by the investigators to be clinically relevant were chosen for analysis (see Additional file [1](#S1){ref-type="supplementary-material"}). A test for proportional hazards using the Schoenfeld residuals was performed, and for covariates indicating evidence of non-proportionality, spline smooth estimates of time-dependent hazard ratios (HRs) with point-wise confidence bands were calculated \[[@B32]\]. Variables that were significant in the univariate analysis after Bonferroni adjustment for multiple testing (*P*-value \<0.05/*k* where *k* is the number of variables tested) were entered into a multivariate Cox proportional hazards model to determine independent risk factors for death. A final set of predictors for each of 28-day and 6-month mortality was selected from these variables via a stepwise Cox proportional hazards regression model. R software version 2.11.1 was used for all data analysis.

Results
=======

Between 29 September 2005 and 13 October 2009, 1,170 patients were enrolled. Four individuals were excluded because of missing or inconsistent data. Patient characteristics are shown in Table  [1](#T1){ref-type="table"}. On admission, 1,135 patients (97%) met IDSA/ATS criteria for severe CAP, 991 on major criteria and 146 on minor criteria.

###### 

Demographic data for patients with CAP admitted to adult ICUs across Europe

  **Case mix**                           **Number analysed**   **Number**   **(%)**
  ------------------------------------- --------------------- ------------ ---------
  Age                                           1,166                           
   \<24 years                                                      23          2
   24 to \<34 years                                                54         4.6
   34 to \<44 years                                               118        10.1
   44 to \<54 years                                               146        12.5
   54 to \<64 years                                               237        20.3
   64 to \<74 years                                               286        24.5
   74 to \<84 years                                               247        21.2
   ≥84 years                                                       55         4.7
  Gender                                        1,166                           
   Male                                                           722        61.9
   Female                                                         444        38.1
  Race                                          1,152                           
   African                                                         17         1.5
   Asian                                                           11          1
   Caucasian                                                      940        81.6
   Hispanic                                                        34          3
   Indian                                                          3          0.3
   Mediterranean                                                  147        12.8
  Country                                       1,166                           
   Belgium                                                        147        12.6
   Czech Republic                                                  40         3.4
   Germany                                                         35          3
   Estonia                                                         17         1.5
   Spain                                                          194        16.6
   France                                                          97         8.3
   Greece                                                          6          0.5
   Croatia                                                         4          0.3
   Ireland                                                         21         1.8
   Israel                                                          5          0.4
   Italy                                                           51         4.4
   Netherlands                                                     2          0.2
   Poland                                                          50         4.3
   Serbia                                                          2          0.2
   United Kingdom                                                 495        42.5
  Medical co-morbidities                                                        
   Heart and vascular disease                   1,164             458        39.3
   Respiratory disease                          1,163             531        45.7
   Neurological disease                         1,164             153        13.1
   Severe renal disease                         1,134              79          7
   Gastrointestinal disease                     1,164             139        11.9
   Malignancy                                   1,164             108         9.3
   Diabetes                                     1,164             228        19.6
   Other illness                                1,164             145        12.5
  Days in ICU                                   1,166                           
   \<3                                                            103         8.8
   3 to \<7                                                       286        24.5
   7 to \<14                                                      311        26.7
   14 to \<28                                                     257         22
   28 to \<56                                                     160        13.7
   56 to 250                                                       49         4.2
  Days in hospital from ICU admission           1,166                           
   \<7                                                             63         5.4
   7 to \<14                                                      200        17.2
   14 to \<28                                                     310        26.6
   28 to \<56                                                     224        19.2
   56 to \<250                                                    126        10.8

Median age was 64 years (range 18 to 101, IQR 51 to 71): 62% were male, 81% were Caucasian and 13% Mediterranean, and 509 patients were hospitalised for more than 24 hours prior to ICU admission. Of these the mean time from hospital admission to ICU admission was 1.04 days. Median length of stay in the ICU was 11 days (IQR 6 to 23); median length of stay in hospital was 22 days (IQR 13 to 40) (Table  [1](#T1){ref-type="table"}).

A total of 718 (62%) patients had one or more co-morbid conditions, with cardiac and respiratory disease affecting 458 and 531 patients, respectively. Chronic obstructive pulmonary disease was documented in 278 (23.8%) patients, diabetes mellitus in 19.6% and a chronic neurological condition in 13.1%.

On the day of admission 884 (76%) patients required mechanical ventilation, with the number increasing to 962 patients (84%) within the first week of admission (Table  [2](#T2){ref-type="table"}). Median duration of mechanical ventilation was 7 days: 573 patients (49%) satisfied the criteria for septic shock. The median duration of inotrope/vasopressor support was 3 days. Renal replacement therapy was required during the first week of admission in 10% of patients. Median SOFA score on admission was 6 (IQR 4 to 9) and median APACHE II score was 20 (IQR 15 to 25).

###### 

Severity scoring, physiological variables and changes on chest radiographs

  **Clinical parameters**                         **Number analysed**   **Median or number**   **IQR or %**
  ---------------------------------------------- --------------------- ---------------------- --------------
  Scoring                                                                                            
   APACHE II score                                       1,166                   20              15 to 25
   SOFA II score                                         1,158                   6                4 to 9
   IDSA/ATS criteria for severe CAP                      1,161                 1,140              97.8%
  Physiology                                                                                         
   Highest temperature, °C                               1,160                  38.0           37.2 to 38.6
   Lowest temperature, °C                                1,160                  36.4            35.8 to 37
   Lowest SBP, mmHg                                      1,161                   91             80 to 105
   Lowest MAP, mmHg                                      1,156                   64              56 to 72
   Highest heart rate. bpm                               1,161                  118             101 to 130
   Lowest heart rate. bpm                                1,161                   84              70 to 95
   Highest WCC, ×10^9^/L                                 1,160                  14.2           9.9 to 20.7
   Lowest WCC, ×10^9^/L                                  1,160                  12.5            8.3 to 18
   Lowest platelet count, ×10^9^/L                       1,160                  197             142 to 266
   Haematocrit, %                                        1089                   34.7             30 to 39
   Bicarbonate, mmol/L                                   1049                    22              19 to 26
   Lowest sodium, mmol/L                                 1,159                  136             132 to 139
   Lowest potassium, mEq/L                               1,159                  3.7             3.4 to 4.2
   PCO~2~, mmHg                                          1,144                   24             5.5 to 40
   pH                                                    1,150                  7.33           7.24 to 7.42
   Serum bilirubin, μmol/L                               1,135                   13              8 to 20
   Urea, μmol/L                                          1,068                   11             6.8 to 20
   Urine volume, cL/day                                  1,153                  155            90 to 236.5
   Creatinine, μmol/L                                    1,161                  100             72 to 157
   Respiratory rate, bpm                                 1,154                   27              18 to 35
   P:F ratio, mmHg                                       1,150                  132             86 to 200
   Renal failure during week 1 in ICU                    1,161                  411                37.1
   Need for RRT during week 1 in ICU                     1,161                  189                17.2
   Mechanical ventilation during week 1 in ICU           1,161                  962                85.0
   Septic shock on admission                             1,161                  573                49.4
  Admission CXR changes                                  1166                                        
   Lobar pattern on CXR                                                         507                43.7
   Localised pattern on CXR                                                     290                 25
   Diffuse bilateral changes on CXR                                             340                29.3

All measurements recorded on day 1 of admission to the ICU unless stated otherwise. APACHE, acute physiology and chronic health evaluation; P:F ratio, ratio of the partial pressure to fractional inspired concentration of oxygen; SOFA. sequential organ failure assessment; IDSA/ATS, Infectious Diseases Society of America/American Thoracic Society; SBP, systolic blood pressure; MAP, mean arterial pressure; WCC, white cell count; CXR, chest radiograph.

Chest radiograph appearances were recorded as lobar consolidation in 43.7%, patchy localised consolidation in 25.0% and diffuse, bilateral changes in 29.3%.

A total of 316 (27.3%) patients had died within 6 months of enrolment, 222 (19.0%) in the ICU, 63 in hospital after ICU discharge and 31 between hospital discharge and 6 months following ICU admission. The in-hospital mortality rate was 24.4% and the 28-day mortality rate was 17.3% (see Table  [3](#T3){ref-type="table"} and Figure  [1](#F1){ref-type="fig"}). Mortality was higher in mechanically ventilated patients, (24.9% at 28 days and 33.6% at 6 months) and in patients with septic shock receiving haemodynamic support with inotropes or vasopressors (28.8% and 38.6% respectively). The standardised mortality ratio derived from the APACHE II score was 0.69 (95% CI 0.68, 0.70) \[[@B28]\].

###### 

Mortality rates in a cohort of 1,166 patients with community acquired pneumonia admitted to adult ICUs across Europe

  **Time**    **Mortality status**   **Number**   **%**
  ---------- ---------------------- ------------ -------
  6 months           Alive              848       72.7
                      Dead              316       27.3
  28 days            Alive              964       82.7
                      Dead              202       17.3
  Hospital           Alive              881       75.6
                      Dead              285       24.4
  ICU                Alive              944       81.0
                      Dead              222       19.0

![Kaplan-Meier curve demonstrating survival probability over a 6-month period for patients admitted to ICU with community-acquired pneumonia (CAP).](cc13812-1){#F1}

No causative organism was identified in over a third of patients (Table  [4](#T4){ref-type="table"}). *Streptococcus pneumoniae* (*Pneumococcus*) was the most commonly isolated organism (29% of cases), Positive microbiology was obtained from lung secretions/lavage in 47% of cases; blood culture in 22%; urinary antigen testing in 17%; blood serology in 10%; pleural fluid in 2.3% and other methods in 2%. Bacteraemia was present in 241 (22%) of patients and pleural infection/empyema in 32 (3%). *Pneumococcus* was the commonest organism causing bacteraemia and empyema, accounting for 119 episodes (49%) and 25 episodes (60%) respectively. Atypical organisms and viruses were rarely identified.

###### 

Microbiological isolates from the GenOSept cohort (n = 1,166)

  **Microbiology (organism)**    **Number**   **%**
  ----------------------------- ------------ -------
   *Streptococcus pneumoniae*       333       28.6
   *Staphylococcus aureus*           69        5.9
   *Legionella pneumophilia*         65        5.5
   *Haemophilus influenzae*          56        4.8
   *Pseudomonas aeroginosa*          52        4.5
   *Klebsiella* spp.                 27        2.3
   *Chlamydia psittaci*              10        0.9
   *Mycoplasma pneumoniae*           10        0.9
   Mixed                             64        5.5
   Viral                             16        1.4
   Other                            144       12.4
   Unknown                          427       36.6

Other organisms included: Candida spp. 30 (2.6%), *Escherichia coli* 15 (1.3%), *Streptococcus* spp.12 (1.0%), *Enterobacter* spp. 10 (0.9%), *Serratia Marcesens* 8 (0.7%).

Univariate analysis
-------------------

Isolation of *Staphylococcus aureus*, presence of septic shock, need for mechanical ventilation and renal replacement therapy all showed a strong association with outcome (Table  [5](#T5){ref-type="table"}).

###### 

Univariate Cox proportional hazards models for 28-day and 6-month mortality for patients admitted to the ICU with CAP

                                       **Increment**   **28-day mortality**   **6-month mortality**                                 
  ----------------------------------- --------------- ---------------------- ----------------------- ---------- ------ ------------ ------------
  APACHE II score                                              1.1                 1.08, 1.12         \<1E-14    1.08    1.07-1.1    0.00E + 00
  Staphylococcus aureus                                        1.65                0.99, 2.75         5.59E-02   2.03   1.38, 2.97    3.02E-04
  Haematocrit                               \%                 0.95                0.93, 0.98         2.98E-05   0.96   0.94, 0.98    6.19E-06
  pH value                               0.1 unit              0.7                 0.62, 0.77         2.31E-11   0.75   0.69, 0.82    1.81E-10
  Septic shock                                                 1.98                1.48, 2.64         3.61E-06   1.6     1.28, 2      3.92E-05
  Diffuse bilateral change on CXR                              1.27                 0.94, 1.7         1.14E-01   1.54   1.22, 1.94    2.44E-04
  Bilirubin                              10 μmol/L             1.04                1.02, 1.07         8.64E-04   1.04   1.02, 1.07    2.86E-04
  Creatinine day 1                       10 μmol/L             1.02                1.01, 1.03         1.41E-03   1.02   1.01, 1.03    1.85E-04
  Lowest heart rate day 1                                      1.01                  1, 1.02          2.35E-03   1.01   1.01, 1.02    4.62E-04
  Lowest MAP day 1                                             0.97                0.96, 0.98         4.96E-06   0.98   0.97, 0.99    1.95E-06
  Lowest SBP day 1                         mmHg                0.98                0.97, 0.99         7.09E-08   0.98   0.98, 0.99    5.33E-07
  Need for any ventilatory support                             3.17                1.72, 5.82         2.01E-04   3.63     2.2, 6      5.07E-07
  Mechanical ventilation                                       2.17                1.46, 3.21         1.19E-04   2.21   1.62, 3.03    6.41E-07
  Renal failure in week 1                                      1.99                 1.5, 2.64         2.04E-06   1.65   1.32, 2.07    1.40E-05
  Need for renal replacement week 1                            2.45                 1.8, 3.32         9.00E-09   2.2    1.71, 2.82    6.09E-10
  SOFAday1                                                     1.12                1.08, 1.17         2.14E-08   1.11   1.08, 1.15    3.22E-10
  Urine volume day 1                    100 mL/day             0.97                0.96, 0.99         1.09E-04   0.97   0.96, 0.98    3.90E-06

All values are significant at a type I error rate of 5% after a Bonferroni correction to take account of the multiple testing of 64 variables (a *P*-value \<0.00078 was considered to be statistically significant). Results are adjusted for age and sex. All day-1 variables unless specified otherwise. RRT, renal replacement therapy; MV, mechanical ventilation; NIV, non-invasive ventilation; SBP, systolic blood pressure; MAP, mean arterial pressure.

Multivariate analysis
---------------------

The factors most strongly associated with 28-day mortality were the APACHE II score calculated on day 1 (HR = 1.03, CI 1.01, 1.05) for each 1.0-point increase in score; haematocrit (HR = 0.97, CI 0.95, 0.99) for each 1% absolute increase; pH (HR = 0.83, CI 0.72, 0.95) for each 0.1-point increase and the need for ventilator support (HR = 2.29, CI 1.11, 4.72). Several other factors were associated with 6-month outcome. APACHE II remained significant (HR = 1.03, CI 1.01, 1.05) for each point increase, as did haematocrit (HR = 0.97, CI 0.95, 0.98) for each 1% increase. pH was strongly associated with 6-month outcome (HR = 0.86, CI 0.77, 0.96) for each 0.1 unit increase. Urine output on the first day was also associated with 6-month outcome (HR = 0.98, CI 0.97, 0.99) for each 100-mL increase in urine volume. Less strongly associated with outcome were bilirubin (HR = 1.004, CI 1.001, 1.006) and the lowest measured heart rate (HR = 1.01, CI 1.00, 1.02) for each 1-beat increase. Of the categorical variables, only diffuse bilateral changes on chest radiography (HR = 1.44, CI 1.11, 1.78) and the need for ventilator support (HR = 3.04, CI 1.64, 5.62) were significantly associated with death (Table  [6](#T6){ref-type="table"}).

###### 

Multivariate Cox proportional hazards model for 28-day and 6-month survival for patients admitted to the ICU with CAP

                              **Increment**   **Hazard**   **95% CI**   ***P-*value**
  -------------------------- --------------- ------------ ------------ ---------------
  **28-day mortality**                                                         
   APACHE II score                               1.06      1.03, 1.09     4.23E-05
   Mechanical ventilation                        2.29      1.11, 4.72     2.56E-02
   Haematocrit                     1%            0.97      0.95, 0.99     6.61E-03
   pH value                     0.1 unit         0.83      0.73, 0.95     7.52E-03
  **6-month mortality**                                                        
   APACHE II score                               1.04      1.02, 1.06     5.67E-05
   Mechanical ventilation                        2.68      1.49, 4.85     1.06E-03
   Urine volume day 1          100 mL/day        0.98      0.96, 0.99     1.28E-04
   Lowest heart rate day 1                       1.01      1.0, 1.01      4.60E-02
   Haematocrit                     \%            0.97      0.95, 0.99     4.78E-04
   Diffuse bilateral CXR                         1.38      1.07, 1.78     1.32E-02

Final model is selected using a stepwise regression by Akaike-information-criteria. Results are adjusted for sex. Age correction included in APACHE II score. APACHE, acute physiology and chronic health evaluation; CXR, chest radiography.

Discussion
==========

This large, prospective study of 1,166 patients from 17 different countries provides a contemporary view of patients with severe CAP admitted to ICUs across Europe. The mortality rates were 17% at 28 days, 19% at intensive care discharge, 24% at hospital discharge and 27% at 6 months, giving a standardised mortality ratio based on the APACHE II scores of 0.69 (95% CI 0.68, 0.70).

A number of studies have documented mortality rates for patients with CAP admitted to ICU \[[@B5]-[@B7],[@B9]-[@B22]\]. The considerable heterogeneity in admission policies, study design, guidelines compliance \[[@B21]\], and severity scoring in these studies probably accounts for the wide range of reported mortality rates and makes meaningful comparisons difficult. Most of these studies have used ICU admission rather than severity scores to indicate severe disease. Only three studies \[[@B12],[@B18],[@B21]\] defined censor points for death, which is important as in-hospital mortality increases following ICU discharge by between 15 and 27% \[[@B33]\]. Admission practices in different countries may also lead to large ranges in mortality. Take for instance one study of 395 patients admitted to a Spanish respiratory ICU in the 1990s the mortality rate was 5% but with rates of mechanical ventilation and septic shock of 9% and 2% respectively \[[@B14]\], whereas in a UK study published in 1997 the mortality rate was 58%, with mechanical ventilation and septic shock rates of 96% and 16% respectively \[[@B11]\]. The mortality rates reported here are more in keeping with other recent, large cohorts. The CAPUCI group analysed 529 patients admitted to over 30 Spanish ICUs between 2000 and 2002 and found ICU mortality rates of 28% with associated APACHE II scores of 19 \[[@B21]\]. They included both immunocompetent and immunosuppressed patients. In the 459 immunocompetent individuals the rate of death at ICU discharge was slightly lower at 25%, a figure that is closer to the 19% seen in the GenOSept cohort, (in which immunocompromised patients were excluded). Some studies have examined larger cohorts of patients admitted to hospital with CAP of varying severity, but have reported outcomes for the smaller subgroup of patients admitted to the ICU. The GenIMS investigators, for example examined a population of 1,895 CAP patients; 302 were admitted to the ICU, 52 (17.3%) of whom died during their hospital stay \[[@B3]\]. In the PORT study, 170 of 1,339 patients were admitted to the ICU with an in-hospital mortality rate of 23.3% \[[@B24]\].

The standard censor point for most interventional ICU studies is 28 days, although it is recognised that there is a significant attrition rate post ICU discharge. It is also well-recognised that in CAP patients there is an increased death rate in the months following discharge \[[@B34]\], and in patients with sepsis there is significant excess mortality for at least five years \[[@B35]\]. In one study, the death rate of ICU patients between 28 days and 6 months was 9% in patients with sepsis, similar to the 8% seen in ICU patients without sepsis \[[@B36]\] and the 10% found in the present study. This compares to an increase in mortality from 18.2% at 30 days to 24.8% at 90 days in the subgroup of ICU patients in the PORT study \[[@B24]\] and an increase from 17.3% to 34.8% at 12 months in the GenIMS cohort of ICU patients \[[@B3]\].

Although the microbiological methodology was not standardised, our findings are consistent with previous studies of severe CAP. Notably, *Streptococcus pneumoniae* accounted for 28% of all cases and no aetiological agent was identified in over a third \[[@B37]\]. Within the GenOSept cohort the rate of *Streptococcus pneumoniae* was higher than previously reported and was mirrored by a decrease in the number of cases where no aetiological agent was identified, suggesting that detection rates may have improved, rather than there being a true increase in incidence. Pneumococcal antigen testing in urine and other bodily fluids has become the standard of care in many institutions and has good positive and negative predictive value both in hospitalised CAP patients \[[@B38]\] and in those admitted to ICU \[[@B39]\]. Amongst the 333 patients with confirmed pneumococcal pneumonia in the present study, a total of 429 positive results were obtained. Of these 123 (29%) were positive urinary antigen tests and 42 (10%) were based on positive blood serology. Further evidence to support this apparent increase in detection rates is provided by a recent study that reported detection rates of 50% for *Streptococcus pneumoniae*, with 16% of cases being diagnosed using antigen testing \[[@B21]\]. In comparison, the BTS study from 1992 reported a rate of *Streptococcus pneumoniae* infection of 18%, with positive antigen testing in only 6% of patients \[[@B7],[@B21]\].

In hospitalised patients with CAP, as many as 18 to 29% may involve a viral infection, the virus being the only organism isolated in 10% \[[@B40]\]. Failure to respond to standard antimicrobial therapy means that more patients with viral pneumonia are likely to be admitted to ICU. Certainly patients with co-morbidities have a higher incidence of viral infection. In the present study viral infections were rarely identified. This raises the question as to whether a more aggressive search for viral pathogens should be conducted in all ventilated patients, coupled with more frequent and targeted use of antiviral therapy.

Multivariate analysis identified four variables (APACHE II score, haematocrit, mechanical ventilation and pH) that were independently associated with outcome at both 28 days and 6 months The need for mechanical ventilation was related to a worse outcome at both 28 days and 6 months, consistent with other data showing respiratory failure to be an independent predictor of mortality in many categories of critically ill patients \[[@B28],[@B29]\]. The persistence of this relationship for up to 6 months reflects the fact that many patients who have received ventilator support will continue to have significant neuromuscular weakness and be at risk for a prolonged period after discharge from the ICU \[[@B41]\]. It may be that over-aggressive use of intravenous fluids, reflected in a dilutional reduction in haematocrit worsens lung injury and thus prolongs the need for mechanical ventilation. Conservative fluid management has been associated with better outcomes, albeit in the later phases of critical illness \[[@B42]\]. A key element of early goal-directed therapy in patients with sepsis is blood transfusion to maintain the haematocrit, perhaps accounting for the positive association between better outcomes and a higher haematocrit in the present, and other studies \[[@B43]\]. Similarly the positive independent relationship between a higher pH on admission and a better outcome may reflect more effective early resuscitation.

Although there was no association between the admission P:F ratio and outcome, diffuse bilateral changes on the chest radiograph (suggesting a diagnosis of acute lung injury/acute respiratory distress syndrome) independently predicted a worse outcome at 6 months. This is consistent with other studies showing a mortality rate for ARDS much higher than that seen in our cohort of patients with CAP \[[@B41]\].

Urine volume, renal failure and the need for renal replacement therapy were associated with worse outcome in the univariate analysis and there was a clear independent association between urine output and mortality at 6 months. Acute kidney injury (AKI) has been shown to be independently associated with higher ICU and in hospital mortality rates \[[@B44],[@B45]\]. The need for ongoing renal support in those with AKI is estimated to be 14%, perhaps explaining the association with outcome at 6 months.

Other studies have attempted to determine independent risk factors for death from CAP. For example, the presence of septic shock has been associated with odds ratios for risk of death ranging from 2 to 141 but inevitably with wide confidence intervals due to the small numbers of patients included in these analyses \[[@B5],[@B6],[@B15],[@B16],[@B22]\]; also the lack of a consistent censor point complicates interpretation of these findings. We found an association between septic shock and outcome on univariate analysis but this effect was not seen in multivariate analysis, perhaps reflecting improvements in the acute management of shock.

This study has two important limitations. Firstly participating centres were at liberty to decide which patients they would enrol; subjects were not, therefore, enrolled consecutively, thereby introducing a potential for selection bias. Also there was considerable variation in the number of patients recruited in each country and some centres contributed only small numbers of patients. Nevertheless there was a wide range of ages, severity of physiological derangement and co-morbidities, whereas APACHE II scores and ventilation rates were similar to previous studies, suggesting that a significant, systematic selection bias is unlikely. Secondly, microbiological protocols were not standardised. On the other hand our observations therefore reflect current approaches to microbiological diagnosis in routine clinical practice across Europe.

Conclusion
==========

The ICU mortality rate in this contemporary cohort of patients admitted to ICUs across Europe with severe CAP was 19%, rising to 24% at hospital discharge and 27% at 6 months. *Streptococcus pneumoniae* was the commonest cause of CAP, but in many cases the infecting organism was not identified. The need for ventilator support, and the presence of diffuse bilateral infiltrates on the chest radiograph, as well as lower haematocrit, urine volume and pH on admission to ICU were independent predictors of a worse outcome.

Key messages
============

• The mortality rate from severe CAP in patients admitted to ICU is 27% at six months

• *Streptococcus pneumonia* remains the most commonly isolated organism

• No microbiological diagnosis is found in a third of patients

• The need for mechanical ventilation is a strong predictor of a poor outcome

• pH, haematocrit, urine output and diffuse changes on chest radiography all predict a worse outcome
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